Virtus ETF Advisers’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
|
|||||
|
2024
Q4 | $67.9K | Buy |
|
|||||
|
2024
Q3 | $86K | Buy |
|
|||||
|
2024
Q2 | $92K | Buy |
|
|||||
|
2024
Q1 | $101K | Sell |
|
|||||
|
2023
Q4 | $102K | Sell |
|
|||||
|
2023
Q3 | $72.4K | Sell |
|
|||||
|
2023
Q2 | $98.1K | Buy |
|
|||||
|
2023
Q1 | $90.4K | Sell |
|
|||||
|
2022
Q4 | $155K | Sell |
|
|||||
|
2022
Q3 | $136K | Buy |
|
|||||
|
2022
Q2 | $130K | Buy |
|
|||||
|
2022
Q1 | $141K | Sell |
|
|||||
|
2021
Q4 | $169K | Sell |
|
|||||
|
2021
Q3 | $425K | Sell |
|
|||||
|
2021
Q2 | $278K | Sell |
|
|||||
|
2021
Q1 | $339K | Buy |
|
|||||
|
2020
Q4 | $283K | Buy |
|
|||||
|
2018
Q2 | – | Sell |
|
|||||
|
2018
Q1 | $597K | Buy |
|
|||||
|
2017
Q4 | $338K | Sell |
|
|||||
|
2017
Q3 | $400K | Buy |
|
|||||
|
2017
Q2 | $314K | Buy |
|
|||||
|
2017
Q1 | $272K | Buy |
|
|||||
|
2016
Q4 | $241K | Buy |
|
|||||
|
2016
Q3 | $241K | Hold |
|
|||||
|
2016
Q2 | $261K | Buy |
|
|||||
|
2016
Q1 | $65K | Buy |
|